Post on 14-Apr-2018
transcript
Boehringer Ingelheim one year ago
Animal Health
Biopharma
Prescription Medicines
Consumer Health Care
Generics
Annual Press Conference 2017 4
• Prescription medicines
• Consumer health care
• Animal health
• Biopharmaceutical contract manufacturing
• Generics
Boehringer Ingelheim today
Annual Press Conference 2017 5
• Human pharmaceuticals
• Animal health
• Biopharmaceutical contract manufacturing
Animal Health Human Pharmaceuticals
Biopharma- ceuticals
ONE Human Pharma
BU Human Pharma
Allan Hillgrove
Innovation Dr Michel
Pairet
Animal Health
Dr Joachim Hasenmaier
Human Resources Dr Andreas Neumann
Finance Simone Menne
Annual Press Conference 2017 6
CEO Hubertus
von Baumbach
Functional organisation structure
Net sales expectations exceeded
Net sales:
15.9 billion euros
+ 7.3%*
Operating income:
2.9 billion euros
+ 26.6%
Return on sales:
18.1% +2.8 percentage
points
*currency-adjusted
Annual Press Conference 2017 10
R&D expenditure:
3.1 billion euros
+3.6%
10.2 12.0
+2.9 -0.1 -1.0
Financial funds
Financial funds
2016
Cash flow from operating activities
Cash flow from investing activities
Cash flow from financing activities
2015
(in EUR billion)
• Financial funds of EUR 12 billion safequard independence and financial mobility
• Cash flow from operating activities significantly exceeds investments in tangible assets
High liquidity and equity safeguard independence
Annual Press Conference 2017 12
Total assets: EUR 26.1 billion
Sound equity structure:
• Equity of EUR 11.3 billion equivalent to equity ratio of 43.3%
• Tangible and intangible assets covered more than three times by equity
High liquidity and equity safeguard independence
Assets Liabilities & Equity
Tangible assets
Other assets
Equity
Pension provisions
Other liabilities
Annual Press Conference 2017 13
1.5
1.6
0.6
Others
Growth in all businesses
Sales growth of businesses (currency-adjusted):
• Prescription medicines (PM): +7.4%
• Animal health (AH): +8.5%
• Consumer health care (CHC): +5.5%
• Biopharmaceutical contract manufacturing (BIO): +6.4%
in EUR billion
CHC 12.0
PM
Annual Press Conference 2017 15
AH
BIO
Prescription medicines: net sales expectations exceeded
• 76% of group net sales • +7.4% (currency-adjusted) compared with previous year
• Net sales of important products,
growth currency-adjusted
• spiriva® EUR 3.0 billion (-14.9%)
• pradaxa® EUR 1.4 billion (+6.8%)
• trajenta®/jentadueto®* EUR 1.1 billion (+23.1%)
• ofev® EUR 0.6 billion (+106.4%)
Annual Press Conference 2017 16
in EUR billion
12.0
PM
*in collaboration with Eli Lilly and Company
Animal health: net sales outperform the market
• 9% of group net sales • +8.5% (currency-adjusted) compared with previous year
• Net sales of important products, growth
currency-adjusted
• ingelvac circoflex® 283 EUR million (+2.9%)
• ingelvac prrs® 114 EUR million (+16.3%)
• metacam® 106 EUR million (+7.1%)
• duramune® 100 EUR million (+13.6%)
Annual Press Conferencez 2017 17
1.5
in EUR billion
AH
Consumer health care: successful final year
• 10% of group net sales • +5.5% (currency-adjusted) compared with previous year
• Net sales of important products, growth
currency-adjusted
• dulcolax® 237 EUR million (+7.7%)
• buscopan® 236 EUR million (+15.1%)
• pharmaton® 145 EUR million (+9.8%)
• mucosolvan® 136 EUR million (-15.5%)
Annual Press Conference 2017 18
1.6
in EUR billion
CHC
Biopharmaceutical contract manufacturing: increase in net sales
• 4% of group net sales • +6.4% compared with previous year
Annual Press Conference 2017 19
0.6 BIO
in EUR billion
Asia/ Australia/Africa
4,226 million euros
+9.7%
Americas
6,542 million euros
-1.6%
Americas region records highest net sales
Europe
5,082 million euros
+19.0%*
*One-off effect from AbbVie payment included
Net sales development, currency-adjusted
Annual Press Conference 2017 20
Strong contribution to European economy
Source: WifOR 2016 / Basis: Financial figures 2014 Annual Press Conference 2017 23
Multiplier for additional jobs
in the EU 8.5
billion euros gross value added
Improvements to operating conditions in Germany needed
Annual Press Conference 2017 25
34% of global
workforce
38% of global R&D
spendings
42% of total investments
6% of total net
sales
2,338
5,533
10,891 12,036
1993 2003 2013 2016
Sustainable success achieved
Net sales of prescription medicines in millions of euros
*in collaboration with Eli Lilly and Company
Annual Press Conference 2017 27
*
*
*
*
*
*
More than
10,000 employees
Products in more than
150 markets
Presence in
99 countries
Animal health: strong together
Annual Press Conference 2017 30
Animal health: outgrowing the market on a sustainable basis
Targets:
• Completing successful integration
• More than doubling Animal Health net sales through Merial integration in 2017
• Outgrowing market on a sustainable basis
• In future investing 8-10 per cent of Animal Health net sales in R&D
Annual Press Conference 2017 31
Human pharmaceuticals: further growth with strong therapeutic areas
• Respiratory diseases
• Cardiometabolic diseases
• Oncology
• Diseases of the central nervous system
• Immunology
Annual Press Conference 2017 33
Human pharmaceuticals: further growth with strong therapeutic areas
jardiance®* reduces relative risk of dying from cardiovascular diseases among patients with type 2 diabetes and pre-existing cardiovascular diseases by more than one third.
Annual Press Conference 2017 34
*in collaboration with Eli Lilly and company
Human pharmaceuticals: further growth with strong therapeutic areas
praxbind® reverses the effect of the pradaxa® oral anticoagulant in just a few minutes
Annual Press Conference 2017 35
Human pharmaceuticals: further growth with strong therapeutic areas
spiolto® respimat® - our further development for the treatment of chronic obstructive pulmonary disease (COPD)
Annual Press Conference 2017 36
Human pharmaceuticals: further growth with strong therapeutic areas
ofev®, for the treatment of idiopathic pulmonary fibrosis, market leader in many countries - to date some 25,000 patients treated
Annual Press Conference 2017 37
Human pharmaceuticals: further growth with strong therapeutic areas
giotrif® for the treatment of lung cancer with an EGFR mutation
Annual Press Conference 2017 38
Human pharmaceuticals: providing patients with new solutions
• Diabetes: jardiance®* to treat chronic heart failure with and without diabetes
• Oncology: nintedanib for the treatment of mesothelioma
• Nintedanib in further fibrotic diseases
• Biosimilars: biosimilar candidates in oncology and immunology
• Immunology: approval of IL-23 inhibitor** expected in 2019
*in collaboration with Eli Lilly and company **in partnership with AbbVie
Annual Press Conference 2017 39
Human pharmaceuticals: early research projects
• Research into secondary diseases in diabetes and CNS diseases
• New area immuno-oncology
• More partnerships with universities, scientific institutes and biotech companies
• Research outside our indication areas – “Research beyond borders”
• Get involved in early technologies via Boehringer Ingelheim Venture Fund
Annual Press Conference 2017 40
Major investments in biopharmaceutical production capacity
• Many decades of competence in biopharmaceutical contract manufacturing
• Investment of almost 700 million euros, including infrastructure, in Vienna biopharmaceutical site
Annual Press Conference 2017 42
Outlook for financial year 2017
• 2017 significant increase in currency-adjusted net sales expected
Annual Press Conference 2017 44